Advertisement

Journal of Cancer Survivorship

, Volume 12, Issue 3, pp 407–416 | Cite as

The continuum of breast cancer care and outcomes in the U.S. Military Health System: an analysis by benefit type and care source

  • Yvonne L. Eaglehouse
  • Stephanie Shao
  • Wenyaw Chan
  • Derek Brown
  • Janna Manjelievskaia
  • Craig D. Shriver
  • Kangmin Zhu
Article
  • 97 Downloads

Abstract

Purpose

This study investigates transition rates between breast cancer diagnosis, recurrence, and death by insurance benefit type and care source in U.S. Military Health System (MHS).

Methods

The MHS data repository and central cancer registry linked data were used to identify women aged 40–64 with histologically confirmed breast cancer between 2003 and 2007. Three-state continuous time Markov models were used to estimate transition rates and transition rate ratios (TRRs) by TRICARE benefit type (Prime or non-Prime) and care source (direct, purchased, or both), adjusted for demographic, tumor, and treatment variables.

Results

Analyses included 2668 women with transitions from diagnosis to recurrence (n = 832), recurrence to death (n = 79), and diagnosis to death without recurrence (n = 91). Compared to women with Prime within each care source, women with non-Prime using both care sources had higher transition rates (TRR 1.47, 95% CI 1.03, 2.10). Compared to those using direct care within each benefit type, women utilizing both care sources with non-Prime had higher transition rates (TRR 1.86, 95% CI 1.11, 3.13), while women with Prime utilizing purchased care had lower transition rates (TRR 0.82, 95% CI 0.68, 0.98).

Conclusions

In the MHS, women with non-Prime benefit plans compared to Prime had higher transition rates along the breast cancer continuum among both care source users. Purchased care users had lower transition rates than direct care users among Prime beneficiaries.

Implications for Cancer Survivors

Benefit plan and care source may be associated with breast cancer progression. Further research is needed to demonstrate differences in survivorship.

Keywords

Health services Breast cancer Insurance Recurrence Survival 

Notes

Acknowledgements

This project was supported by the John P. Murtha Cancer Center, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center under the auspices of the Henry M. Jackson Foundation for the Advancement of Military Medicine. The original data linkage was supported by the former United States Military Cancer Institute and Division of Cancer Epidemiology and Genetics, National Cancer Institute. The authors thank the following institutes for their contributions to the original data linkage project: ICF Macro, Kennel and Associates, Inc., the Defense Health Agency, the Joint Pathology Center and former Armed Forces Institute of Pathology, and the National Cancer Institute.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Disclaimer

The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views, assertions, opinions, or policies of the Uniformed Services University of the Health Sciences (USUHS), the Department of Defense (DoD), or the Departments of the Army, Navy, or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government.

Supplementary material

11764_2018_680_MOESM1_ESM.pdf (269 kb)
ESM 1 (PDF 269 kb)

References

  1. 1.
    Hassett MJ, Neville BA, Weeks JC. The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst. 2014;106(10).Google Scholar
  2. 2.
    Boero IJ, Paravati AJ, Triplett DP, Hwang L, Matsuno RK, Mell LK, et al. The impact of radiotherapy costs on clinical outcomes in breast cancer. Radiother Oncol. 2015;117(2):393–9.Google Scholar
  3. 3.
    Rong X, Yang W, Garzon-Muvdi T, Caplan JM, Hui X, Lim M, et al. Influence of insurance status on survival of adults with glioblastoma multiforme: a population-based study. Cancer. 2016;122:3157–65.  https://doi.org/10.1002/cncr.30160.
  4. 4.
    Naghavi AO, Echevarria MI, Grass GD, Strom TJ, Abuodeh YA, Ahmed KA, et al. Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies. Cancer. 2016;122:3529–37.  https://doi.org/10.1002/cncr.30212.
  5. 5.
    Zhang Y, Franzini L, Chan W, Xu H, Du XL. Effects of health insurance on tumor stage, treatment, and survival in large cohorts of patients with breast and colorectal cancer. J Health Care Poor Underserved. 2015;26(4):1336–58.  https://doi.org/10.1353/hpu.2015.0119.CrossRefPubMedGoogle Scholar
  6. 6.
    Landrum MB, Keating NL, Lamont EB, Bozeman SR, Krasnow SH, Shulman L, et al. Survival of older patients with cancer in the veterans health administration versus fee-for-service Medicare. J Clin Oncol. 2012;30(10):1072–9.  https://doi.org/10.1200/jco.2011.35.6758.
  7. 7.
    Wang CJ, Cheng SH, Wu JY, Lin YP, Kao WH, Lin CL, et al. Association of a Bundled-Payment Program with cost and outcomes in full-cycle breast cancer care. JAMA Oncology. 2017;3(3):327–34.  https://doi.org/10.1001/jamaoncol.2016.4549.
  8. 8.
    Lee-Feldstein A, Feldstein PJ, Buchmueller T, Katterhagen G. The relationship of HMOs, health insurance, and delivery systems to breast cancer outcomes. Med Care. 2000;38(7):705–18.CrossRefPubMedGoogle Scholar
  9. 9.
    Defense Health Agency. TRICARE. 2016. www.tricare.mil.
  10. 10.
    Jansen DJ. Military Medical Care: Questions and Answers. In: Congressional Research Service, editor. www.crs.gov2014.
  11. 11.
    Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000;56(1):167–72.CrossRefPubMedGoogle Scholar
  12. 12.
    Li YP, Chan W. Analysis of longitudinal multinomial outcome data. Biometrical journal Biometrische Zeitschrift. 2006;48(2):319–26.Google Scholar
  13. 13.
    Gilard-Pioc S, Abrahamowicz M, Mahboubi A, Bouvier AM, Dejardin O, Huszti E, et al. Multi-state relative survival modelling of colorectal cancer progression and mortality. Cancer Epidemiol. 2015;39(3):447–55.  https://doi.org/10.1016/j.canep.2015.03.005.CrossRefPubMedGoogle Scholar
  14. 14.
    Enewold L, McGlynn KA, Zahm SH, Jatoi I, Anderson WF, Gill AA, et al. Surveillance mammography among female Department of Defense beneficiaries: a study by race and ethnicity. Cancer. 2013;119(19):3531–8.  https://doi.org/10.1002/cncr.28242.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Enewold LR, McGlynn KA, Zahm SH, Poudrier J, Anderson WF, Shriver CD, et al. Breast reconstruction after mastectomy among Department of Defense beneficiaries by race. Cancer. 2014;120(19):3033–9.  https://doi.org/10.1002/cncr.28806.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMedGoogle Scholar
  17. 17.
    American Joint Committee on Cancer. Breast. In: Eds. F.L. Greene, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al., editors. AJCC Cancer Staging Manual. Sixth Edition ed. United States of America: Springer; 2002. p. 223–40.Google Scholar
  18. 18.
    Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value in health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008;11(2):213–20.CrossRefGoogle Scholar
  19. 19.
    TRICARE Management Activity, Office of the Chief Financial Officer-Defense Health Cost Assessment and Program Evaluation. Evaluation of the TRICARE Program: Access, Cost, and Quality. http://www.tricare.mil/tma/studeiseval.aspx2012.
  20. 20.
    Defense Health Agency, Defense Health Cost Assessment and Program Evaluation. Evaluation of the TRICARE Program: Access, Cost, and Quality. http://www.tricare.mil/tma/studieseval.aspx2014.
  21. 21.
    Zullig LL, Williams CD, Fortune-Britt AG. Lung and colorectal cancer treatment and outcomes in the veterans affairs health care system. Cancer Manag Res. 2015;7:19–35.  https://doi.org/10.2147/cmar.s75463.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lauria MM. Continuity of cancer care. Cancer. 1991;67(6 Suppl):1759–66.CrossRefPubMedGoogle Scholar
  23. 23.
    Field TS, Buist DS, Doubeni C, Enger S, Fouayzi H, Hart G, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst. 2005;35:88–95.  https://doi.org/10.1093/jncimonographs/lgi044.CrossRefGoogle Scholar
  24. 24.
    Jatoi I, Becher H, Leake CR. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. Cancer. 2003;98(5):894–9.  https://doi.org/10.1002/cncr.11604.CrossRefPubMedGoogle Scholar
  25. 25.
    Schinkel JK, Zahm SH, Jatoi I, McGlynn KA, Gallagher C, Schairer C, et al. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the surveillance, epidemiology, and end results data. Cancer Causes Control. 2014;25(8):959–68.  https://doi.org/10.1007/s10552-014-0395-1.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73.  https://doi.org/10.1001/jama.2014.17322.CrossRefPubMedGoogle Scholar
  27. 27.
    Maskarinec G, Sen C, Koga K, Conroy SM. Ethnic differences in breast cancer survival: status and determinants. Women's Health (Lond Engl). 2011;7(6):677–87.  https://doi.org/10.2217/whe.11.67.CrossRefGoogle Scholar
  28. 28.
    Enewold L, Zhou J, McGlynn KA, Devesa SS, Shriver CD, Potter JF, et al. Racial variation in tumor stage at diagnosis among Department of Defense beneficiaries. Cancer. 2012;118(5):1397–403.  https://doi.org/10.1002/cncr.26208.CrossRefPubMedGoogle Scholar
  29. 29.
    Enewold L, Zhou J, McGlynn KA, Anderson WF, Shriver CD, Potter JF, et al. Racial variation in breast cancer treatment among Department of Defense beneficiaries. Cancer. 2012;118(3):812–20.  https://doi.org/10.1002/cncr.26346.CrossRefPubMedGoogle Scholar
  30. 30.
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. 2017. www.nccn.org. Accessed: 6 April 2017.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Yvonne L. Eaglehouse
    • 1
    • 2
  • Stephanie Shao
    • 1
  • Wenyaw Chan
    • 3
  • Derek Brown
    • 1
  • Janna Manjelievskaia
    • 1
  • Craig D. Shriver
    • 1
    • 2
  • Kangmin Zhu
    • 1
    • 4
  1. 1.John P. Murtha Cancer CenterUniformed Services University of the Health Sciences and Walter Reed National Military Medical CenterRockvilleUSA
  2. 2.Department of SurgeryUniformed Services University of the Health SciencesBethesdaUSA
  3. 3.University of Texas Health Science Center at HoustonHoustonUSA
  4. 4.Department of Preventive Medicine and BiostatisticsUniformed Services University of the Health SciencesBethesdaUSA

Personalised recommendations